AR110412A1 - Inhibidores de la cyp11a1 - Google Patents

Inhibidores de la cyp11a1

Info

Publication number
AR110412A1
AR110412A1 ARP170103609A ARP170103609A AR110412A1 AR 110412 A1 AR110412 A1 AR 110412A1 AR P170103609 A ARP170103609 A AR P170103609A AR P170103609 A ARP170103609 A AR P170103609A AR 110412 A1 AR110412 A1 AR 110412A1
Authority
AR
Argentina
Prior art keywords
alkyl
methyl
pyran
isoquinolinyl
dihydro
Prior art date
Application number
ARP170103609A
Other languages
English (en)
Spanish (es)
Inventor
Gerd Wohlfahrt
Matti Vaismaa
Eija Tiainen
Petteri Rummakko
Pekka Pietikinen
Mikko Passiniemi
Mikko Mkel
Belle David Din
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of AR110412A1 publication Critical patent/AR110412A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
ARP170103609A 2016-12-22 2017-12-20 Inhibidores de la cyp11a1 AR110412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20166024 2016-12-22

Publications (1)

Publication Number Publication Date
AR110412A1 true AR110412A1 (es) 2019-03-27

Family

ID=61005837

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103609A AR110412A1 (es) 2016-12-22 2017-12-20 Inhibidores de la cyp11a1

Country Status (30)

Country Link
US (4) US10717726B2 (enExample)
EP (2) EP3558981B1 (enExample)
JP (2) JP7025432B2 (enExample)
KR (3) KR102826021B1 (enExample)
CN (2) CN116162084B (enExample)
AR (1) AR110412A1 (enExample)
AU (2) AU2017380282B2 (enExample)
CA (1) CA3047370A1 (enExample)
CL (1) CL2019001728A1 (enExample)
CO (1) CO2019007321A2 (enExample)
CY (1) CY1124461T1 (enExample)
DK (1) DK3558981T3 (enExample)
EA (1) EA039309B1 (enExample)
ES (1) ES2880151T3 (enExample)
HR (1) HRP20211255T1 (enExample)
HU (1) HUE056540T2 (enExample)
IL (2) IL267484B (enExample)
LT (1) LT3558981T (enExample)
MA (2) MA55983A (enExample)
MX (1) MX388538B (enExample)
PE (1) PE20191137A1 (enExample)
PH (1) PH12019550111A1 (enExample)
PL (1) PL3558981T3 (enExample)
PT (1) PT3558981T (enExample)
RS (1) RS62198B1 (enExample)
SI (1) SI3558981T1 (enExample)
TN (1) TN2019000189A1 (enExample)
TW (2) TWI762544B (enExample)
UA (1) UA124640C2 (enExample)
WO (1) WO2018115591A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1
CN115551831A (zh) * 2020-05-14 2022-12-30 奥赖恩公司 Cyp11a1抑制剂
CN116724034B (zh) * 2020-12-01 2026-06-05 奥赖恩公司 作为用于治疗前列腺癌的cyp11a1抑制剂的2,3-二氢-4h-苯并[b][1,4]噁嗪-4-基)(5-(苯基)-吡啶-3-基)甲酮衍生物和类似化合物
CN117279893A (zh) 2021-03-01 2023-12-22 奥仁公司 用于制备cyp11a1抑制剂及其中间体的方法
AR124985A1 (es) 2021-03-01 2023-05-24 Orion Corp Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
CN117242070A (zh) * 2021-03-01 2023-12-15 奥仁公司 4h-吡喃-4-酮结构化cyp11a1抑制剂的固体形式
AU2022297768A1 (en) 2021-06-23 2024-01-18 Orion Corporation Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
EP4408426A1 (en) * 2021-09-28 2024-08-07 Orion Corporation Cyp11a1 inhibitor for use in the treatment of prostate cancer
WO2023073285A1 (en) 2021-10-28 2023-05-04 Orion Corporation Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor
EP4430027A1 (en) 2021-11-10 2024-09-18 Orion Corporation Cyp11a1 inhibitors
KR20240130101A (ko) 2022-01-20 2024-08-28 오리온 코포레이션 Cyp11a1 억제제의 약제 조성물
CN118307519A (zh) * 2023-01-06 2024-07-09 上海闻耐医药科技有限公司 一类cyp11a1抑制剂化合物及其制备方法和用途
KR20240126916A (ko) 2023-02-14 2024-08-22 경북대학교 산학협력단 Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물
TW202440557A (zh) 2023-03-29 2024-10-16 大陸商西藏海思科製藥有限公司 Cyp11a1抑制劑及其用途
JP2026514915A (ja) 2023-04-21 2026-05-13 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Cyp11a1阻害剤及びその用途
KR20260040160A (ko) * 2023-05-11 2026-03-24 셴젠 이오노바 라이프 사이언스 시오., 엘티디. Cyp11a1 억제제로서의 신규 화합물 및 그 용도
EP4746854A1 (en) 2023-07-19 2026-05-27 Orion Corporation Stable pharmaceutical compositions of a cyp11a1 inhibitor
WO2025021182A1 (en) * 2023-07-27 2025-01-30 Acerand Therapeutics (Hong Kong) Limited Cyp11a1 inhibitors
CN121889383A (zh) * 2023-09-08 2026-04-17 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用
WO2025168117A1 (zh) * 2024-02-08 2025-08-14 盛睿泽华医药科技(苏州)有限公司 一种多环化合物及其制备方法和应用
WO2025237211A1 (zh) * 2024-05-11 2025-11-20 辽宁海思科制药有限公司 一种cyp11a1抑制剂的晶型物及其制备方法和应用
TW202613102A (zh) * 2024-05-27 2026-04-01 大陸商遼寧海思科製藥有限公司 Cyp11a1抑制劑的鹽及其晶型、其製備方法和應用
WO2026021515A1 (zh) * 2024-07-25 2026-01-29 海思科制药(眉山)有限公司 一种cyp11a1抑制剂的制备方法
WO2026040949A1 (zh) * 2024-08-19 2026-02-26 辽宁海思科制药有限公司 一种cyp11a1抑制剂的药物组合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6176485A (ja) * 1984-09-20 1986-04-18 Ss Pharmaceut Co Ltd 新規なγ−ピラン誘導体
WO2003074450A2 (en) * 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
EP1471063A1 (en) * 2003-02-28 2004-10-27 Exonhit Therapeutics S.A. Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
US20140005181A1 (en) 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
TW201534586A (zh) * 2013-06-11 2015-09-16 Orion Corp 新穎cyp17抑制劑/抗雄激素劑
AR110412A1 (es) 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1

Also Published As

Publication number Publication date
EP3868756A1 (en) 2021-08-25
IL285729B (en) 2022-02-01
MA55983A (fr) 2022-03-23
TWI762544B (zh) 2022-05-01
JP2022078068A (ja) 2022-05-24
TW202229264A (zh) 2022-08-01
AU2021203497A1 (en) 2021-07-01
US20210347765A1 (en) 2021-11-11
MA47102B1 (fr) 2021-09-30
IL267484B (en) 2021-09-30
MX2019007373A (es) 2019-09-18
EA201991513A1 (ru) 2019-11-29
PE20191137A1 (es) 2019-09-02
JP7025432B2 (ja) 2022-02-24
KR20250097993A (ko) 2025-06-30
EP3558981B1 (en) 2021-05-26
CO2019007321A2 (es) 2019-07-31
KR102491308B1 (ko) 2023-01-27
TWI796205B (zh) 2023-03-11
HRP20211255T1 (hr) 2021-11-12
JP7286825B2 (ja) 2023-06-05
TW201835072A (zh) 2018-10-01
AU2017380282A1 (en) 2019-08-01
PL3558981T3 (pl) 2021-12-06
MX388538B (es) 2025-03-20
US11098032B2 (en) 2021-08-24
AU2021203497B2 (en) 2022-11-10
HUE056540T2 (hu) 2022-02-28
KR20190095950A (ko) 2019-08-16
NZ755395A (en) 2025-10-31
LT3558981T (lt) 2021-08-25
US10717726B2 (en) 2020-07-21
KR102826021B1 (ko) 2025-06-30
WO2018115591A1 (en) 2018-06-28
CN110139861B (zh) 2022-12-30
AU2017380282B2 (en) 2021-06-24
JP2020502229A (ja) 2020-01-23
CA3047370A1 (en) 2018-06-28
CN110139861A (zh) 2019-08-16
PT3558981T (pt) 2021-07-06
PH12019550111A1 (en) 2020-03-09
SI3558981T1 (sl) 2021-09-30
UA124640C2 (uk) 2021-10-20
EP3558981A1 (en) 2019-10-30
CL2019001728A1 (es) 2019-09-27
RS62198B1 (sr) 2021-08-31
IL267484A (en) 2019-08-29
CY1124461T1 (el) 2022-07-22
BR112019012906A2 (pt) 2019-12-03
CN116162084A (zh) 2023-05-26
KR20230019496A (ko) 2023-02-08
ES2880151T3 (es) 2021-11-23
CN116162084B (zh) 2025-12-09
IL285729A (en) 2021-09-30
US12030871B2 (en) 2024-07-09
US20240308989A1 (en) 2024-09-19
DK3558981T3 (da) 2021-07-26
US20190359601A1 (en) 2019-11-28
EA039309B1 (ru) 2022-01-12
US20200299280A1 (en) 2020-09-24
TN2019000189A1 (en) 2020-10-05

Similar Documents

Publication Publication Date Title
AR122049A2 (es) Derivados de pirimidiniloxi benceno como herbicidas
AR112529A1 (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos en el tratamiento de diversos tipos de cáncer
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR089807A1 (es) Compuestos de imidazopirrolidinona
AR101692A1 (es) Compuestos y métodos para inhibir histonas demetilasas
AR111241A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
AR104259A1 (es) Inhibidores de bromodominio
AR096643A1 (es) Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo)
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
AR089051A1 (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos
AR104720A1 (es) Moduladores de ccr2
Srinivas et al. Synthesis and characterization of novel oxazines and demonstration that they specifically target cyclooxygenase 2
JP2017505762A5 (enExample)
AR062503A1 (es) Derivados de pirido[2, 3-d]pirimidina y pirazin[2, 3-d]pirimidina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de mtor.
AR103265A1 (es) Compuestos de azolina sustituidos con un sistema de anillos condensado
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине
AR082914A1 (es) Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos
AR098492A1 (es) Derivados de purina
CL2019001728A1 (es) Derivados de pirano como inhibidores de cyp11a1 (citocromo p450 monooxigenasa 11a1).
AR113346A1 (es) Derivados de picolinamida microbicidas
AR094272A1 (es) Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo
AR096023A1 (es) Amidas fungicidas

Legal Events

Date Code Title Description
FG Grant, registration